EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An orally available P1′-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier

Nobuyo Higashi-Kuwata iD, Haydar Bulut iD, Hironori Hayashi iD, Kohei Tsuji iD, Hiromi Ogata-Aoki iD, Maki Kiso iD, Nobutoki Takamune iD, Naoki Kishimoto iD, Shin-Ichiro Hattori iD, Takahiro Ishii iD, Takuya Kobayakawa iD, Kenta Nakano iD und 16 weitere

PNAS Nexus · 23.12.2024 · 4 (1)

DOI: 10.1093/pnasnexus/pgae578 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PNAS Nexus, online erschienen am 07.01.2025. Verfasst von Nobuyo Higashi-Kuwata und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-865…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Institute, National Institutes of Health, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We identified a 5-fluoro-benzothiazole-containing small molecule, TKB272, through fluorine-scanning of the benzothiazole moiety, which more potently inhibits the enzymatic activity of SARS-CoV-2's main protease (Mpro) and more effectively blocks the infectivity and replication of all SARS-CoV-2 strains examined including Omicron variants such as SARS-CoV-2XBB1.5 and SARS-CoV-2EG.5.1 than two Mpro inhibitors: nirmatrelvir and ensitrelvir. Notably, the administration of ritonavir-boosted nirmatrelvir and ensitrelvir causes drug–drug interactions warranting cautions due to their CYP3A4 inhibition, thereby limiting their clinical utility. When orally administered, TKB272 blocked SARS-CoV-2XBB1.5 replication without ritonavir in B6.Cg-Tg(K18-hACE2)2-Prlmn/J-transgenic mice, comparably as did ritonavir-boosted nirmatrelvir. When the ancestral SARS-CoV-2 was propagated with nirmatrelvir in vitro, a highly nirmatrelvir-resistant E166V-carrying variant (SARS-CoV-2E166V−P14) readily emerged by passage 14; however, when propagated with TKB272, no variants emerged by passage 25. SARS-CoV-2E166V showed some cross-resistance to TKB272 but was substantially sensitive to the compound. X-ray structural analyses and mass-spectrometric data showed that the E166V substitution disrupts the critical dimerization-initiating Ser1′-E166 interactions, thereby limiting nirmatrelvir's Mpro inhibition but that TKB272 nevertheless forms a tight binding with Mpro's catalytic active sight even in the presence of the E166V substitution. TKB272 shows no apparent genotoxicity as tested in the micro-Ames test. Highly potent TKB272 may serve as a COVID-19 therapeutic, overcome resistance to existing Mpro inhibitors.

Schlagwörter

Stichwörter der Autor:innen

COVID-19Mpro inhibitorSARS-CoV-2fluorine-scanninggenetic barrier

Autor:innen und Institutionen

  • Department of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
  • Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
  • Department of Infectious Diseases, International Research Institute of Disaster Science, Tohoku University, Aoba-ku, Sendai 980-8575, Japan.
  • Department of Medicinal Chemistry, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Chiyoda-ku, Tokyo 101-0062, Japan.
  • Department of Clinical Sciences, Kumamoto University Hospital, Chuo-ku, Kumamoto 860-8556, Japan.
  • Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection & Graduate School of Medical Sciences, Kumamoto University, Chuo-ku, Kumamoto 860-0811, Japan.

ORCID-Profile: Nobuyo Higashi-Kuwata, Haydar Bulut, Hironori Hayashi, Kohei Tsuji, Hiromi Ogata-Aoki, Maki Kiso, Nobutoki Takamune, Naoki Kishimoto, Shin-Ichiro Hattori, Takahiro Ishii, Takuya Kobayakawa, Kenta Nakano, Yukiko Shimizu, Debananda Das, Junji Saruwatari, Kazuya Hasegawa, Kazutaka Murayama, Yoshikazu Sukenaga, Yuki Takamatsu, Manabu Aoki, Yuri Furusawa, Tadashi Okamura, Seiya Yamayoshi, Yoshihiro Kawaoka, Shogo Misumi, Hirokazu Tamamura, Hiroaki Mitsuya

Förderung

  • National Cancer Institute
  • National Institutes of Health
  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development
  • Department of Health and Human Services of the United States
  • National Center for Global Health and Medicine

Zitieren

APA

Higashi-Kuwata, N., Bulut, H., Hayashi, H., Tsuji, K., Ogata-Aoki, H., Kiso, M., Takamune, N., Kishimoto, N., Hattori, S. I., Ishii, T., Kobayakawa, T., Nakano, K., Shimizu, Y., Das, D., Saruwatari, J., Hasegawa, K., Murayama, K., Sukenaga, Y., Takamatsu, Y., …, & Mitsuya, H. (2024). An orally available P1′-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier. PNAS Nexus, 4(1). https://doi.org/10.1093/pnasnexus/pgae578

Vancouver

Higashi-Kuwata N, Bulut H, Hayashi H, Tsuji K, Ogata-Aoki H, Kiso M, et al. An orally available P1′-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier. PNAS Nexus. 2024;4(1). doi:10.1093/pnasnexus/pgae578

BibTeX
@article{HigashiKuwata2024,
  author = {Higashi-Kuwata, Nobuyo and Bulut, Haydar and Hayashi, Hironori and Tsuji, Kohei and Ogata-Aoki, Hiromi and Kiso, Maki and Takamune, Nobutoki and Kishimoto, Naoki and Hattori, Shin-Ichiro and Ishii, Takahiro and Kobayakawa, Takuya and Nakano, Kenta and Shimizu, Yukiko and Das, Debananda and Saruwatari, Junji and Hasegawa, Kazuya and Murayama, Kazutaka and Sukenaga, Yoshikazu and Takamatsu, Yuki and Yoshimura, Kazuhisa and Aoki, Manabu and Furusawa, Yuri and Okamura, Tadashi and Yamayoshi, Seiya and Kawaoka, Yoshihiro and Misumi, Shogo and Tamamura, Hirokazu and Mitsuya, Hiroaki},
  title = {An orally available P1′-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier},
  journal = {PNAS Nexus},
  year = {2024},
  volume = {4},
  number = {1},
  doi = {10.1093/pnasnexus/pgae578}
}
Kostenlos starten →